{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:43:11Z","timestamp":1762508591783,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.dld.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T06:51:04Z","timestamp":1630219864000},"page":"684-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-ent\u00e9rologues Oncologues (AGEO) multicentre study"],"prefix":"10.1016","volume":"54","author":[{"given":"Claire","family":"Gallois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Hafliger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Perret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9lia","family":"Coutzac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pellat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violaine","family":"Randrian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Basile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Faroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Locher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lola-Jade","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Dior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Artru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2021.08.009_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.dld.2021.08.009_bib0002","first-page":"8","article-title":"Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity","volume":"12","author":"Deboever","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.dld.2021.08.009_bib0003","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ejca.2013.03.004","article-title":"Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history","volume":"49","author":"Kelly","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2021.08.009_bib0004","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.1996.14.3.716","article-title":"ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group","volume":"14","author":"Zalcberg","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0005","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","article-title":"Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group","volume":"16","author":"Cocconi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0006","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/oxfordjournals.annonc.a010800","article-title":"Final results of a randomised trial comparing \u201cTomudex\u201d (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. \u2018Tomudex\u2019 Colorectal Cancer Study Group","volume":"7","author":"Cunningham","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0007","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdf183","article-title":"Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients","volume":"13","author":"Seitz","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0008","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1023\/A:1011194712661","article-title":"Second-line treatment with oxaliplatin\u00a0+\u00a0raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine\/leucovorin-based chemotherapy","volume":"12","author":"Scheithauer","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0009","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00001813-200208000-00006","article-title":"Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial","volume":"13","author":"Neri","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.dld.2021.08.009_bib0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/annonc\/mdf091","article-title":"Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)","volume":"13","author":"Cascinu","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0011","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12094-012-0843-x","article-title":"A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer","volume":"14","author":"Gravalos","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0012","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3748\/wjg.v23.i8.1406","article-title":"Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis","volume":"23","author":"Guo","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2021.08.009_bib0013","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/sj.bjc.6602860","article-title":"Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer","volume":"93","author":"Feliu","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2021.08.009_bib0014","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000084821","article-title":"First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study","volume":"68","author":"Aparicio","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.dld.2021.08.009_bib0015","doi-asserted-by":"crossref","first-page":"v179","DOI":"10.1093\/annonc\/mdx393.055","article-title":"Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)","volume":"28","author":"Samalin","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0016","doi-asserted-by":"crossref","first-page":"ix39","DOI":"10.1093\/annonc\/mdz421.036","article-title":"Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): an interim analysis of a multicenter phase II trial","volume":"30","author":"Zhu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12029-009-9060-4","article-title":"Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer","volume":"39","author":"Geurs","year":"2008","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.dld.2021.08.009_bib0018","doi-asserted-by":"crossref","unstructured":"CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf n.d.","DOI":"10.2118\/0310-014-TWA"},{"key":"10.1016\/j.dld.2021.08.009_bib0019","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.08.009_bib0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0021","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","article-title":"Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma","volume":"32","author":"Rivera","year":"2017","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.dld.2021.08.009_bib0022","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: a Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.08.009_bib0023","first-page":"64","article-title":"Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: large Single-Center Experience","volume":"18","author":"Khan","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.dld.2021.08.009_bib0024","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12029-009-9101-z","article-title":"Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma","volume":"40","author":"Paiva","year":"2009","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.dld.2021.08.009_bib0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1055\/s-2006-927004","article-title":"Iatrogenic acute coronary syndrome\"\u201359 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil","volume":"44","author":"Gundling","year":"2006","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.dld.2021.08.009_bib0026","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/bjc.1998.160","article-title":"Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity","volume":"77","author":"K\u00f6hne","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2021.08.009_bib0027","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.08.009_bib0028","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0029","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0031","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.ejca.2008.07.002","article-title":"Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)","volume":"44","author":"Popov","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2021.08.009_bib0032","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00002018-200023040-00001","article-title":"Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer","volume":"23","author":"Jansman","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.dld.2021.08.009_bib0033","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/annonc\/mdf054","article-title":"Raltitrexed: current clinical status and future directions","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2021.08.009_bib0034","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821004564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821004564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:19:50Z","timestamp":1761625190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821004564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1590865821004564"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.08.009","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-ent\u00e9rologues Oncologues (AGEO) multicentre study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}